NYSE Listed Company Manual

Arcus Biosciences Announces New Employment Inducement Grants

Retrieved on: 
Tuesday, July 25, 2023
Oncology, Health, General Health, Research, Science, Pharmaceutical, Biotechnology, Cancer, NYSE Listed Company Manual, NYSE, Compensated emancipation, Pharmaceutical industry

Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company’s Board of Directors granted five new employees options to purchase a total of 21,200 shares of the Company’s common stock at an exercise price per share of $19.50, which was the closing price on July 24, 2023, and restricted stock units to acquire a total of 10,600 shares of the Company’s common stock.

Key Points: 
  • Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company’s Board of Directors granted five new employees options to purchase a total of 21,200 shares of the Company’s common stock at an exercise price per share of $19.50, which was the closing price on July 24, 2023, and restricted stock units to acquire a total of 10,600 shares of the Company’s common stock.
  • The equity awards were granted pursuant to the Company’s 2020 Inducement Plan, which was approved by the Company’s Board of Directors in January 2020 pursuant to the “inducement exception” under NYSE Listed Company Manual Rule 303A.08.

Atento Announces Delisting from NYSE; Delisting expected in Restructuring Plan

Retrieved on: 
Friday, July 21, 2023
NYSE Listed Company Manual, Growth, NYSE, OTC, Cryptocurrency, Security (finance), Financial adviser, Atento

Delisting is contemplated by the previously announced comprehensive financial restructuring plan aimed at optimizing financial and operational efficiency and driving long-term growth.

Key Points: 
  • Delisting is contemplated by the previously announced comprehensive financial restructuring plan aimed at optimizing financial and operational efficiency and driving long-term growth.
  • Delisting affects only the shares of Atento S.A. at a holding company level so will not affect business operations.
  • The delisting will only affect the shares of Atento S.A. at a holding company level and so will not affect business operations.
  • The restructuring plan provides for interim financing to a comprehensive financial restructuring aimed at optimizing financial and operational efficiency and driving long-term growth.

Yelp Announces New Employee Inducement Grants Under NYSE Rule 303A.08

Retrieved on: 
Friday, July 21, 2023
Online Retail, Retail, Restaurant, Bar, Apps, Applications, Technology, Software, Internet, NYSE Listed Company Manual, Inc., Employment, Professional Football Compensation Committee, Yelp, NYSE, Compensated emancipation, Pharmaceutical industry

Yelp Inc. (NYSE: YELP), the company that connects people with great local businesses, announced that on July 17, 2023, the Compensation Committee of Yelp’s Board of Directors granted inducement restricted stock unit awards covering 62,122 shares of Yelp’s common stock to four new non-executive employees to induce them to accept employment with Yelp.

Key Points: 
  • Yelp Inc. (NYSE: YELP), the company that connects people with great local businesses, announced that on July 17, 2023, the Compensation Committee of Yelp’s Board of Directors granted inducement restricted stock unit awards covering 62,122 shares of Yelp’s common stock to four new non-executive employees to induce them to accept employment with Yelp.
  • Each award was granted under the Yelp Inc. 2023 Inducement Award Plan and vests over a four-year period, subject to continued employment with Yelp through each vesting date.
  • Each award was granted as a material inducement to employment in accordance with the NYSE Listed Company Manual Rule 303A.08.

LION ELECTRIC ANNOUNCES FINANCING TRANSACTIONS FOR APPROXIMATE AGGREGATE GROSS PROCEEDS OF US$142 MILLION

Retrieved on: 
Monday, July 17, 2023
Exercise, NYSE Listed Company Manual, Indian stock exchange, EV, Interest, Funding, Toronto Stock Exchange, Conglomerate (company), IQ, Investissement Québec, Government, Convertible, Public expenditure, Lion Electric Company, VWAP, Nature, Convertible bond, TSX, Mirella, NYSE, News, Debenture, Cryptocurrency, Security (finance), Warrant, Montréal–Mirabel International Airport

Combined financing transactions representing aggregate gross proceeds of approximately US$142 million provides flexibility to execute growth plans;

Key Points: 
  • Combined financing transactions representing aggregate gross proceeds of approximately US$142 million provides flexibility to execute growth plans;
    Company to extend the maturity of its senior credit facilities by one year to August, 2025 concurrently with closing;
    Company to cancel its ATM program.
  • MONTREAL, July 17, 2023 /PRNewswire/ - The Lion Electric Company (NYSE: LEV) (TSX: LEV) ("Lion" or the "Company"), a leading manufacturer of all-electric medium and heavy-duty urban vehicles, announced today that the Company has entered into subscription agreements with investors contemplating concurrent financing transactions for aggregate gross proceeds to the Company of approximately US$142 million (the "Financing").
  • "This financing transaction represents a key milestone for Lion, as it provides us with flexibility to execute our growth plans.
  • assuming only IQ converts its Convertible Debentures into Common Shares and no other share issuance by the Company), prior to the date of closing of the Financing.

Phreesia Acquires MediFind, Reinforcing its Commitment to Patient-Centered Care and Expanding its Offerings to Consumers

Retrieved on: 
Friday, July 14, 2023
Technology, Health Technology, Professional Services, Software, Managed Care, Health, Data Analytics, General Health, Artificial Intelligence, Product management, NYSE Listed Company Manual, Employment, Arm, Senior, Noise, Cancer, Thought, Patient, Machine learning, Diagnosis, Nursing, Management

MediFind assigns four levels of expertise to those doctors: elite, distinguished, advanced and experienced.

Key Points: 
  • MediFind assigns four levels of expertise to those doctors: elite, distinguished, advanced and experienced.
  • Elite-level doctors are global leaders in their field who hold leadership positions, publish and speak regularly, and are involved in cutting-edge treatments.
  • MediFind CEO Patrick Howie founded the company after his brother was diagnosed with a rare cancer, and he experienced firsthand how challenging it was to find high-quality experts and treatments.
  • Each award was granted as a material inducement to employment in accordance with the NYSE Listed Company Manual Rule 303A.08.

Arcus Biosciences Announces New Employment Inducement Grants

Retrieved on: 
Tuesday, July 11, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Cancer, NYSE Listed Company Manual, NYSE, Compensated emancipation, Pharmaceutical industry

Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company’s Board of Directors granted eight new employees options to purchase a total of 20,600 shares of the Company’s common stock at an exercise price per share of $21.88, which was the closing price on July 10, 2023, and restricted stock units to acquire a total of 10,300 shares of the Company’s common stock.

Key Points: 
  • Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company’s Board of Directors granted eight new employees options to purchase a total of 20,600 shares of the Company’s common stock at an exercise price per share of $21.88, which was the closing price on July 10, 2023, and restricted stock units to acquire a total of 10,300 shares of the Company’s common stock.
  • The equity awards were granted pursuant to the Company’s 2020 Inducement Plan, which was approved by the Company’s Board of Directors in January 2020 pursuant to the “inducement exception” under NYSE Listed Company Manual Rule 303A.08.

NYSE to Commence Delisting Proceedings with Respect to the Warrants of Doma Holdings, Inc. (DOMA WS)

Retrieved on: 
Tuesday, July 11, 2023
Professional Services, Finance, NYSE Listed Company Manual, Exchange, Bangladesh Securities and Exchange Commission, Committee, Warrant, New York Stock Exchange, Security (finance), DOMA, NYSE

The New York Stock Exchange (“NYSE”, the “Exchange”) announced today that the staff of NYSE Regulation has determined to commence proceedings to delist the warrants of Doma Holdings, Inc. (the “Company”), every 25 warrants will be exercisable for one share of common stock, at an exercise price of $287.50 (the “Warrants”)— ticker symbol DOMA WS — from the NYSE.

Key Points: 
  • The New York Stock Exchange (“NYSE”, the “Exchange”) announced today that the staff of NYSE Regulation has determined to commence proceedings to delist the warrants of Doma Holdings, Inc. (the “Company”), every 25 warrants will be exercisable for one share of common stock, at an exercise price of $287.50 (the “Warrants”)— ticker symbol DOMA WS — from the NYSE.
  • Trading in the Company’s Warrants will be suspended immediately.
  • Trading in the Company’s common stock — ticker symbol DOMA — will continue on the NYSE.
  • NYSE Regulation has determined that the Company’s Warrants are no longer suitable for listing based on “abnormally low” price levels, pursuant to Section 802.01D of the Listed Company Manual.

Owlet, Inc. Announces NYSE Acceptance of Continued Listing Compliance Plan

Retrieved on: 
Tuesday, July 11, 2023
Technology, Parenting, Children, Baby, Maternity, Other Health, Health, Consumer, General Health, Consumer Electronics, NYSE Listed Company Manual, Common stock, Pediatrics, Stock split, Notice, Development, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, NYSE, Food, OWLT, Owlet

Owlet, Inc. (NYSE: OWLT) (“Owlet” or the “Company”) today announced that the New York Stock Exchange (“NYSE”) has accepted the Company’s business plan to regain compliance with the continued listing standards set forth in Section 802.01B of the NYSE Listed Company Manual.

Key Points: 
  • Owlet, Inc. (NYSE: OWLT) (“Owlet” or the “Company”) today announced that the New York Stock Exchange (“NYSE”) has accepted the Company’s business plan to regain compliance with the continued listing standards set forth in Section 802.01B of the NYSE Listed Company Manual.
  • Based upon a review of the compliance plan and information submitted by the Company, the NYSE has accepted the submission.
  • The Company’s Class A common stock (“Common Stock”) will continue to be listed on the NYSE during such time, subject to the Company’s compliance with other continued listing standards.
  • The Company will also be subject to quarterly monitoring by the NYSE for compliance with the plan.

BIT Mining Limited Receives Notice Regarding NYSE Continued Listing Standards

Retrieved on: 
Friday, July 7, 2023
NYSE Listed Company Manual, American depositary receipt, Letter, BIT, NYSE, Mining, Market capitalization, Cryptocurrency

The Company intends to develop and submit such a business plan to the NYSE.

Key Points: 
  • The Company intends to develop and submit such a business plan to the NYSE.
  • The notice has no immediate impact on the listing of the Company's American Depositary Shares ("ADSs"), which will continue to be listed and traded on the NYSE, subject to compliance with other NYSE continued listing standards and other rights of the NYSE to delist the ADSs.
  • The Company is currently in compliance with all other NYSE continued listing standards.
  • The NYSE notice does not affect the Company's business operations, its U.S. Securities and Exchange Commission reporting requirements, or its contractual obligations.

Innovid Regains Compliance with NYSE Continued Listing Standards

Retrieved on: 
Wednesday, July 5, 2023
NYSE Listed Company Manual, CTV, Innovid, NYSE

NEW YORK, July 5, 2023 /PRNewswire/ -- Innovid Corp. (NYSE:CTV) (the "Company"), an independent advertising platform for delivery, personalization, and measurement of converged TV across linear, connected TV (CTV) and digital, today announced that, based on a notification letter the Company received from the New York Stock Exchange (the "NYSE") on July 3, 2023, the Company has regained compliance with the NYSE's continued listing standards for minimum share price under Section 802.01C of the NYSE Listing Company Manual.

Key Points: 
  • NEW YORK, July 5, 2023 /PRNewswire/ -- Innovid Corp. (NYSE:CTV) (the "Company"), an independent advertising platform for delivery, personalization, and measurement of converged TV across linear, connected TV (CTV) and digital, today announced that, based on a notification letter the Company received from the New York Stock Exchange (the "NYSE") on July 3, 2023, the Company has regained compliance with the NYSE's continued listing standards for minimum share price under Section 802.01C of the NYSE Listing Company Manual.
  • On May 18, 2023, NYSE had notified Innovid that it was not in compliance with the NYSE's continued listing standards because the average closing price of the Company's common stock was less than $1.00 per share over a 30 trading-day period.
  • On July 3, 2023, the Company received a confirmation from the NYSE that, as of June 30, 2023, the Company's average stock price had a closing share price of at least $1.00 and had maintained an average closing share price of at least $1.00 over the 30 trading-day period ending on that date.
  • Accordingly, the Company's shares are no longer considered to be below the minimum share price requirement of Section 802.01C and, a result, the Company has regained compliance with the NYSE continued listing standards and will continue to be traded on the NYSE.